Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Chronic MK-801 Application in Adolescence and Early Adulthood: A Spatial Working Memory Deficit in Adult Long-Evans Rats But No Changes in the Hippocampal NMDA Receptor Subunits

L. Uttl, T. Petrasek, H. Sengul, M. Svojanovska, V. Lobellova, K. Vales, D. Radostova, G. Tsenov, H. Kubova, A. Mikulecka, J. Svoboda, A. Stuchlik,

. 2018 ; 9 (-) : 42. [pub] 20180212

Language English Country Switzerland

Document type Journal Article

Grant support
NV17-30833A MZ0 CEP Register

The role of NMDA receptors in learning, memory and hippocampal function has long been recognized. Post-mortem studies have indicated that the expression or subunit composition of the NMDA glutamate receptor subtype might be related to the impaired cognitive functions found in schizophrenia patients. NMDA receptor antagonists have been used to develop animal models of this disorder. There is accumulating evidence showing that not only the acute but also the chronic application of NMDA receptor antagonists may induce schizophrenia-like alterations in behavior and brain functions. However, limited evidence is available regarding the consequences of NMDA receptor blockage during periods of adolescence and early adulthood. This study tested the hypothesis that a 2-week treatment of male Long-Evans and Wistar rats with dizocilpine (MK-801; 0.5 mg/kg daily) starting at postnatal days (PD) 30 and 60 would cause a long-term cognitive deficit and changes in the levels of NMDA receptor subunits. The working memory version of the Morris water maze (MWM) and active place avoidance with reversal on a rotating arena (Carousel) requiring cognitive coordination and flexibility probed cognitive functions and an elevated-plus maze (EPM) was used to measure anxiety-like behavior. The western blot method was used to determine changes in NMDA receptor subunit levels in the hippocampus. Our results showed no significant changes in behaviors in Wistar rats. Slightly elevated anxiety-like behavior was observed in the EPM in Long-Evans rats with the onset of treatment on PD 30. Furthermore, Long-Evans rats treated from PD 60 displayed impaired working memory in the MWM. There were; however, no significant changes in the levels of NMDA receptor subunits because of MK-801 administration. These findings suggest that a 2-week treatment starting on PD 60 in Long-Evans rats leads to long-term changes in working memory, but this deficit is not paralleled by changes in NMDA receptor subunits. These results support the face validity, but not construct validity of this model. We suggest that chronic treatment of adolescent and adult rats does not constitute a plausible animal model of schizophrenia.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18009975
003      
CZ-PrNML
005      
20180404145230.0
007      
ta
008      
180404s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2018.00042 $2 doi
035    __
$a (PubMed)29487522
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Uttl, Libor $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia. Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czechia.
245    10
$a Chronic MK-801 Application in Adolescence and Early Adulthood: A Spatial Working Memory Deficit in Adult Long-Evans Rats But No Changes in the Hippocampal NMDA Receptor Subunits / $c L. Uttl, T. Petrasek, H. Sengul, M. Svojanovska, V. Lobellova, K. Vales, D. Radostova, G. Tsenov, H. Kubova, A. Mikulecka, J. Svoboda, A. Stuchlik,
520    9_
$a The role of NMDA receptors in learning, memory and hippocampal function has long been recognized. Post-mortem studies have indicated that the expression or subunit composition of the NMDA glutamate receptor subtype might be related to the impaired cognitive functions found in schizophrenia patients. NMDA receptor antagonists have been used to develop animal models of this disorder. There is accumulating evidence showing that not only the acute but also the chronic application of NMDA receptor antagonists may induce schizophrenia-like alterations in behavior and brain functions. However, limited evidence is available regarding the consequences of NMDA receptor blockage during periods of adolescence and early adulthood. This study tested the hypothesis that a 2-week treatment of male Long-Evans and Wistar rats with dizocilpine (MK-801; 0.5 mg/kg daily) starting at postnatal days (PD) 30 and 60 would cause a long-term cognitive deficit and changes in the levels of NMDA receptor subunits. The working memory version of the Morris water maze (MWM) and active place avoidance with reversal on a rotating arena (Carousel) requiring cognitive coordination and flexibility probed cognitive functions and an elevated-plus maze (EPM) was used to measure anxiety-like behavior. The western blot method was used to determine changes in NMDA receptor subunit levels in the hippocampus. Our results showed no significant changes in behaviors in Wistar rats. Slightly elevated anxiety-like behavior was observed in the EPM in Long-Evans rats with the onset of treatment on PD 30. Furthermore, Long-Evans rats treated from PD 60 displayed impaired working memory in the MWM. There were; however, no significant changes in the levels of NMDA receptor subunits because of MK-801 administration. These findings suggest that a 2-week treatment starting on PD 60 in Long-Evans rats leads to long-term changes in working memory, but this deficit is not paralleled by changes in NMDA receptor subunits. These results support the face validity, but not construct validity of this model. We suggest that chronic treatment of adolescent and adult rats does not constitute a plausible animal model of schizophrenia.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Petrasek, Tomas $u Department of Neurophysiology of Memory, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
700    1_
$a Sengul, Hilal $u Department of Neurophysiology of Memory, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia. Radboud Institute for Molecular Life Sciences, Radboud University, Nijmegen, Netherlands.
700    1_
$a Svojanovska, Marketa $u Department of Neurophysiology of Memory, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
700    1_
$a Lobellova, Veronika $u Department of Neurophysiology of Memory, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
700    1_
$a Vales, Karel $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czechia. Department of Neurophysiology of Memory, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
700    1_
$a Radostova, Dominika $u Department of Neurophysiology of Memory, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia. Second Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Tsenov, Grygoriy $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
700    1_
$a Kubova, Hana $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
700    1_
$a Mikulecka, Anna $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
700    1_
$a Svoboda, Jan $u Department of Neurophysiology of Memory, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
700    1_
$a Stuchlik, Ales $u Department of Neurophysiology of Memory, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 9, č. - (2018), s. 42
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29487522 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180404145310 $b ABA008
999    __
$a ind $b bmc $g 1287460 $s 1006787
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 9 $c - $d 42 $e 20180212 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
GRA    __
$a NV17-30833A $p MZ0
LZP    __
$a Pubmed-20180404

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...